FRATAXAV Trademark

Trademark Overview

On Thursday, July 20, 2023, a trademark application was filed for FRATAXAV with the United States Patent and Trademark Office. The USPTO has given the FRATAXAV trademark a serial number of 79382527. The federal status of this trademark filing is REGISTERED as of Tuesday, February 11, 2025. This trademark is owned by BIOINTAXIS, S.L.. The FRATAXAV trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical products for the treatment of cardiac and neurological diseases
frataxav

General Information

Serial Number79382527
Word MarkFRATAXAV
Filing DateThursday, July 20, 2023
Status700 - REGISTERED
Status DateTuesday, February 11, 2025
Registration Number7683057
Registration DateTuesday, February 11, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 24, 2024

Trademark Statements

Goods and Servicespharmaceutical products for the treatment of cardiac and neurological diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 6, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBIOINTAXIS, S.L.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressES
Party NameBIOINTAXIS, S.L.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressES
Party NameBIOINTAXIS, S.L.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressES

Trademark Events

Event DateEvent Description
Thursday, November 2, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, November 6, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 10, 2023APPLICATION FILING RECEIPT MAILED
Monday, March 25, 2024ASSIGNED TO EXAMINER
Tuesday, April 16, 2024NON-FINAL ACTION WRITTEN
Monday, April 29, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, April 17, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, October 25, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, April 29, 2024REFUSAL PROCESSED BY MPU
Wednesday, May 22, 2024REFUSAL PROCESSED BY IB
Sunday, September 29, 2024ASSIGNED TO EXAMINER
Friday, October 25, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, October 25, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 25, 2024TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, October 25, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, October 25, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, October 28, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, October 28, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, October 29, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 27, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 18, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, November 27, 2024ASSIGNED TO EXAMINER
Tuesday, December 24, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 24, 2024PUBLISHED FOR OPPOSITION
Tuesday, February 11, 2025REGISTERED-PRINCIPAL REGISTER
Tuesday, February 11, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED
Monday, March 31, 2025NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Monday, March 31, 2025NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Saturday, April 19, 2025NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sunday, May 11, 2025FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, August 27, 2025FINAL DISPOSITION PROCESSED
Thursday, August 28, 2025FINAL DISPOSITION NOTICE SENT TO IB
Friday, September 19, 2025FINAL DECISION TRANSACTION PROCESSED BY IB

Related Keywords

frataxav neurological diseases cardiac treatment products pharmaceutical